As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Silo Pharma, Inc. The largest reported stake is Mitchell P. Kopin's, at 9.99%. 9 filings are on record since August 12, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like Silo Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 125,261 · Sole dispositive: 0 · Shared dispositive: 125,261 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: AdvisorShares Trust · Sole voting: 75,582 · Shared voting: 0 · Sole dispositive: 75,582 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-08
- · Reporting person: Anson Funds Management LP · Sole voting: 0 · Shared voting: 699,486 · Sole dispositive: 0 · Shared dispositive: 699,486 · SCHEDULE 13G/A, 2026-02-17
- · Holder: SEG Opportunity Fund, LLC · Percent: 0% · Shares: 0 · SCHEDULE 13G/A
- · Holder: Mitchell P. Kopin · Percent: 9.99% · SCHEDULE 13G/A
Silo Pharma, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.99% | 125,261 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| AdvisorShares Trust | 6.69% | 75,582 | SCHEDULE 13G, 2026-07-08 | 2026-06-30 |
| Anson Funds Management LP | 4.9% | 699,486 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| SEG Opportunity Fund, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2026-02-13 |
Holding shares or following this stake? See who's behind Silo Pharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Silo Pharma, Inc. and the records around it.
Silo Pharma, Inc. elsewhere on the record
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- Who owns it
Companies that share a holder
- SEG Opportunity Fund, LLC also filed stake reports on 4 other companies: Volato Group, Inc. (Jul 2026), AUDDIA INC. (Apr 2026)
- AdvisorShares Trust also filed stake reports on 8 other companies: Neuphoria Therapeutics Inc. (Oct 2026), PSYENCE BIOMEDICAL LTD. (Oct 2026), Enveric Biosciences, Inc. (Jan 2026)
- Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)
Watch Silo Pharma, Inc.
Get an email when Silo Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Silo Pharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Silo Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Silo Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mitchell P. Kopin | 0 | 125,261 | 0 | 125,261 | SCHEDULE 13G/A, 2026-08-13 |
| Daniel B. Asher | 0 | 125,261 | 0 | 125,261 | SCHEDULE 13G/A, 2026-08-13 |
| Intracoastal Capital LLC | 0 | 125,261 | 0 | 125,261 | SCHEDULE 13G/A, 2026-08-13 |
| AdvisorShares Trust | 75,582 | 0 | 75,582 | 0 | SCHEDULE 13G, 2026-07-08 |
| Anson Funds Management LP | 0 | 699,486 | 0 | 699,486 | SCHEDULE 13G/A, 2026-02-17 |
| Anson Management GP LLC | 0 | 699,486 | 0 | 699,486 | SCHEDULE 13G/A, 2026-02-17 |
| Tony Moore | 0 | 699,486 | 0 | 699,486 | SCHEDULE 13G/A, 2026-02-17 |
| Anson Advisors Inc. | 0 | 699,486 | 0 | 699,486 | SCHEDULE 13G/A, 2026-02-17 |
| Amin Nathoo | 0 | 699,486 | 0 | 699,486 | SCHEDULE 13G/A, 2026-02-17 |
| Moez Kassam | 0 | 699,486 | 0 | 699,486 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing identifies Silo Pharma, Inc. by CUSIP 82711P300 and gives its principal executive office as 677 N. Washington Boulevard, Sarasota, FL 34236 (SCHEDULE 13G/A, 2026-08-13).
What the percentages are based on
Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 4.9% of the outstanding Common Stock, which includes Ordinary Shares underlying outstanding warrants (each, a "Warrant," and collectively, the "Warrants") held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam.Anson Funds Management LP, SCHEDULE 13G/A, 2026-02-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2025-10-03 | SEG Opportunity Fund, LLC | 7.1% | SCHEDULE 13G |
| 2025-11-07 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Anson Funds Management LP | 7.2% | SCHEDULE 13G |
| 2026-02-13 | SEG Opportunity Fund, LLC | 0% | SCHEDULE 13G/A |
| 2026-02-13 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Anson Funds Management LP | 4.9% | SCHEDULE 13G/A |
| 2026-07-08 | AdvisorShares Trust | 6.69% | SCHEDULE 13G |
| 2026-08-13 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
Questions about who owns Silo Pharma, Inc.
Who owns Silo Pharma, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Silo Pharma, Inc.: Mitchell P. Kopin (9.99%, Schedule 13G/A, filed 2026-08-13) and AdvisorShares Trust (6.69%, Schedule 13G, filed 2026-07-08).
Who are the largest shareholders of Silo Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Silo Pharma, Inc. on this page are Mitchell P. Kopin (9.99%) and AdvisorShares Trust (6.69%).
When did Mitchell P. Kopin buy into Silo Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Mitchell P. Kopin on this page is the Schedule 13G/A, filed 2025-08-12, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Silo Pharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 14, 2026 | Form D, private offering | $4M sold | Form D page | Source |
Silo Pharma, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Silo Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.